Floatz logo

PTC-299

AML

PTC TherapeuticsSmall moleculePhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

50 Active assets in the AML cohort.

Asset / SponsorPhaseRating
AKLAVINE
Chinese PLA General Hospital
Phase 4BB
Elacytarabine
Clavis Pharma
Phase 3BB
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
University Hospital Tuebingen
Phase 2/3BB
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3B
FUROSEMIDE
Memorial Sloan Kettering Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

PTC-299 is also rated in:

breast cancerDormant
CC
Indicative ·
42 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →